David W Ollila

5PUBLICATIONS
75CO-AUTHORS
Predictive and prognostic markersEpigenetics (incl. genome methylation and epigenomics)Cancer therapy (excl. chemotherapy and radiation therapy)Gene expression (incl. microarray and other genome-wide approaches)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Oct 20, 2025
Tumor miRNA Signatures Associate with Outcomes of Patients with Stage II/III Melanoma.

Jennifer M Wiggins, Qiao Zhang, Yian Zhang

|Mar 04, 2025
Association of Inherited Genetic Variants with Multiple Primary Melanoma.

David C Gibbs, Brittany M Small, Isidora Autuori

|May 13, 2022
Pathologic complete response and survival after neoadjuvant chemotherapy in cT1-T2/N0 HER2+ breast cancer.

Selena J An, Emilie D Duchesneau, Paula D Strassle

|Mar 02, 2022
The impact of age and nodal status on variations in oncotype DX testing and adjuvant treatment.

Kathleen Iles, Mya L Roberson, Philip Spanheimer

|Oct 05, 2021
Disease-Associated Risk Variants in ANRIL Are Associated with Tumor-Infiltrating Lymphocyte Presence in Primary Melanomas in the Population-Based GEM Study.

Danielle R Davari, Irene Orlow, Peter A Kanetsky

Pageof 1

Frequent Collaborators

3 joint publications

Irene Orlow

3 joint publications

Sharon N Edmiston

3 joint publications

Anne E Cust

3 joint publications

Colin B Begg